These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21851879)

  • 1. Influence of global region on outcomes in heart failure β-blocker trials.
    O'Connor CM; Fiuzat M; Swedberg K; Caron M; Koch B; Carson PE; Gattis-Stough W; Davis GW; Bristow MR
    J Am Coll Cardiol; 2011 Aug; 58(9):915-22. PubMed ID: 21851879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials.
    Haas SJ; Vos T; Gilbert RE; Krum H
    Am Heart J; 2003 Nov; 146(5):848-53. PubMed ID: 14597934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
    Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J;
    Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-blocker treatment of chronic systolic heart failure improves prognosis even in patients meeting one or more exclusion criteria of the MERIT-HF study.
    Jost A; Rauch B; Hochadel M; Winkler R; Schneider S; Jacobs M; Kilkowski C; Kilkowski A; Lorenz H; Muth K; Zugck C; Remppis A; Haass M; Senges J;
    Eur Heart J; 2005 Dec; 26(24):2689-97. PubMed ID: 16183697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.
    Deedwania PC; Giles TD; Klibaner M; Ghali JK; Herlitz J; Hildebrandt P; Kjekshus J; Spinar J; Vitovec J; Stanbrook H; Wikstrand J;
    Am Heart J; 2005 Jan; 149(1):159-67. PubMed ID: 15660048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial.
    Caro JJ; Migliaccio-Walle K; O'Brien JA; Nova W; Kim J; Hauch O; Hillson E; Wedel H; Hjalmarson A; Gottlieb S; Deedwania PC; Wikstrand J;
    J Card Fail; 2005 Dec; 11(9):647-56. PubMed ID: 16360958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The use of beta blockers in heart failure: clinical studies].
    Cobelli F
    Ital Heart J Suppl; 2000 Aug; 1(8):996-1002. PubMed ID: 10993005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF).
    Gullestad L; Wikstrand J; Deedwania P; Hjalmarson A; Egstrup K; Elkayam U; Gottlieb S; Rashkow A; Wedel H; Bermann G; Kjekshus J;
    J Am Coll Cardiol; 2005 Jan; 45(2):252-9. PubMed ID: 15653024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF.
    Wikstrand J; Wedel H; Castagno D; McMurray JJ
    J Intern Med; 2014 Feb; 275(2):134-43. PubMed ID: 24118421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF.
    Jánosi A; Ghali JK; Herlitz J; Czuriga I; Klibaner M; Wikstrand J; Hjalmarson A;
    Am Heart J; 2003 Oct; 146(4):721-8. PubMed ID: 14564329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors.
    Krum H; Haas SJ; Eichhorn E; Ghali J; Gilbert E; Lechat P; Packer M; Roecker E; Verkenne P; Wedel H; Wikstrand J
    Eur Heart J; 2005 Oct; 26(20):2154-8. PubMed ID: 16014644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS.
    Domanski MJ; Krause-Steinrauf H; Massie BM; Deedwania P; Follmann D; Kovar D; Murray D; Oren R; Rosenberg Y; Young J; Zile M; Eichhorn E;
    J Card Fail; 2003 Oct; 9(5):354-63. PubMed ID: 14583895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials.
    Frazier CG; Alexander KP; Newby LK; Anderson S; Iverson E; Packer M; Cohn J; Goldstein S; Douglas PS
    J Am Coll Cardiol; 2007 Apr; 49(13):1450-8. PubMed ID: 17397674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does tight heart rate control improve beta-blocker efficacy? An updated analysis of the noncardiac surgical randomized trials.
    Beattie WS; Wijeysundera DN; Karkouti K; McCluskey S; Tait G
    Anesth Analg; 2008 Apr; 106(4):1039-48, table of contents. PubMed ID: 18349171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of heart failure with beta-blockers?].
    Osterziel KJ; Dietz R
    Z Kardiol; 1997 Jan; 86(1):1-8. PubMed ID: 9133118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
    J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators.
    Pietrasik G; Goldenberg I; McNitt S; Polonsky B; Moss AJ; Zareba W
    J Cardiovasc Electrophysiol; 2009 Apr; 20(4):395-400. PubMed ID: 19017351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis.
    Bell DS; Lukas MA; Holdbrook FK; Fowler MB
    Curr Med Res Opin; 2006 Feb; 22(2):287-96. PubMed ID: 16466600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial.
    Issa VS; Amaral AF; Cruz FD; Ferreira SM; Guimarães GV; Chizzola PR; Souza GE; Bacal F; Bocchi EA
    Circ Heart Fail; 2010 Jan; 3(1):82-8. PubMed ID: 19933408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population-based analysis of class effect of β blockers in heart failure.
    Lazarus DL; Jackevicius CA; Behlouli H; Johansen H; Pilote L
    Am J Cardiol; 2011 Apr; 107(8):1196-202. PubMed ID: 21349489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.